{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:19:03Z","timestamp":1791811143159,"version":"4.3.4"},"reference-count":81,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The role of secondary cytoreductive surgery (SCS) in the treatment of recurrent ovarian cancer (ROC) has been widely increased in recent years, especially in trying to improve the quality of life of these patients by utilising a minimally-invasive (MI) approach. However, surgery in previously-treated patients may be challenging, and patient selection and surgical planning are crucial. Unfortunately, at the moment, validated criteria to select patients for MI-SCS are not reported, and no predictors of its feasibility are currently available, probably due to the vast heterogeneity of recurrence patterns. The aim of this narrative review is to describe the role of secondary cytoreductive surgery and, in particular, minimally-invasive procedures, in ROC, analyzing patient selection, outcomes, criticisms, and future perspectives.<\/jats:p>","DOI":"10.3390\/cancers15194769","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T07:50:26Z","timestamp":1695887426000},"page":"4769","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Minimally-Invasive Secondary Cytoreduction in Recurrent Ovarian Cancer"],"prefix":"10.3390","volume":"15","author":[{"given":"Camilla","family":"Certelli","sequence":"first","affiliation":[{"name":"Gynecologic Oncology Unit, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"},{"name":"Institute of Obstetrics and Gynecology, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio Andrea","family":"Russo","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Unit, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"},{"name":"Institute of Obstetrics and Gynecology, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9704-3300","authenticated-orcid":false,"given":"Luca","family":"Palmieri","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Unit, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"},{"name":"Institute of Obstetrics and Gynecology, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniello","family":"Foresta","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Unit, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"},{"name":"Institute of Obstetrics and Gynecology, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8036-9323","authenticated-orcid":false,"given":"Luigi","family":"Pedone Anchora","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Unit, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4954-719X","authenticated-orcid":false,"given":"Virginia","family":"Vargiu","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Unit, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Santullo","sequence":"additional","affiliation":[{"name":"Surgical Unit of Peritoneum and Retroperitoneum, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Unit, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Unit, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Gallotta","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Unit, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"ref_1","unstructured":"(2023, January 01). National Cancer Institute, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11912-021-01128-5","article-title":"Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy","volume":"23","author":"Sims","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer","volume":"381","author":"Pautier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"381","author":"Pothuri","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_8","first-page":"189","article-title":"Survival of patients following secondary cytoreductive surgery in ovarian cancer","volume":"61","author":"Berek","year":"1983","journal-title":"Obstet. Gynecol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/IGC.0000000000000598","article-title":"Surgery for Recurrent Epithelial Ovarian Cancer in the Netherlands: A Population-Based Cohort Study","volume":"26","author":"Kruitwagen","year":"2016","journal-title":"Int. J Gynecol. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.3802\/jgo.2019.30.e100","article-title":"The efficacy of secondary cytoreductive surgery for recurrent ovarian, tubal, or peritoneal cancer in Tian-model low-risk patients","volume":"30","author":"So","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"625.e1","DOI":"10.1016\/j.ajog.2019.06.009","article-title":"Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer","volume":"221","author":"Gockley","year":"2019","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2008.08.033","article-title":"Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis","volume":"112","author":"Bristow","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ygyno.2017.02.010","article-title":"A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer","volume":"145","author":"Cowan","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2014.09.017","article-title":"Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial","volume":"136","author":"Lee","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1007\/s00464-013-3390-9","article-title":"Laparoscopic surgical management of localized recurrent ovarian cancer: A single-institution experience","volume":"28","author":"Gallotta","year":"2014","journal-title":"Surg. Endosc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ygyno.2014.05.029","article-title":"Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: A retrospective analysis","volume":"134","author":"Petrillo","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.clon.2018.04.006","article-title":"When should Surgery be used for Recurrent Ovarian Carcinoma?","volume":"30","author":"Bommert","year":"2018","journal-title":"Clin. Oncol. (R Coll. Radiol.)"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.3802\/jgo.2019.30.e116","article-title":"Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer?","volume":"30","author":"Zang","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1200\/JCO.21.02085","article-title":"Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis","volume":"40","author":"Baek","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): A multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ygyno.2013.06.020","article-title":"Ovarian cancer patients with localized relapse: Clinical outcome and prognostic factors","volume":"131","author":"Petrillo","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ygyno.2023.04.002","article-title":"PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients","volume":"173","author":"Gauduchon","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1136\/ijgc-2022-003543","article-title":"Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance","volume":"22","author":"Palluzzi","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.ejso.2021.01.033","article-title":"Minimally invasive surgical staging for early stage ovarian cancer: A long-term follow up","volume":"47","author":"Gallotta","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jmig.2016.03.006","article-title":"Laparoscopic Versus Laparotomic Surgical Staging for Early-Stage Ovarian Cancer: A Case-Control Study","volume":"23","author":"Gallotta","year":"2016","journal-title":"J. Minim. Invasive Gynecol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jmig.2016.11.004","article-title":"Robotic Versus Laparoscopic Staging for Early Ovarian Cancer: A Case-Matched Control Study","volume":"24","author":"Gallotta","year":"2017","journal-title":"J. Minim. Invasive Gynecol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1097\/AOG.0000000000003507","article-title":"Intraoperative Capsule Rupture, Postoperative Chemotherapy, and Survival of Women With Stage I Epithelial Ovarian Cancer","volume":"134","author":"Matsuo","year":"2019","journal-title":"Obstet. Gynecol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1002\/cncr.23390","article-title":"Prognostic factors for high-risk early-stage epithelial ovarian cancer: A Gynecologic Oncology Group study","volume":"112","author":"Chan","year":"2008","journal-title":"Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/jnci\/95.2.113","article-title":"European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial","volume":"95","author":"Trimbos","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ygyno.2019.03.257","article-title":"The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer","volume":"153","author":"Algera","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ygyno.2017.05.022","article-title":"Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes","volume":"146","author":"Eriksson","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ygyno.2014.05.007","article-title":"Feasibility and perioperative outcomes of robotic-assisted surgery in the management of recurrent ovarian cancer: A multi-institutional study","volume":"134","author":"Escobar","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ygyno.2013.01.015","article-title":"Analysis of secondary cytoreduction for recurrent ovarian cancer by robotics, laparoscopy and laparotomy","volume":"129","author":"Magrina","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_36","unstructured":"(2023, July 01). ESGO-ESMO-ESP Consensus Conference on Ovarian Cancer 2022 presented by Anna Fagotti at ESGO Congress Berlin. Available online: https:\/\/esgo.org\/esgo-2022\/."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ygyno.2015.02.004","article-title":"External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer","volume":"137","author":"Massuger","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jmig.2018.01.007","article-title":"Robotic Surgery in Elderly and Very Elderly Gynecologic Cancer Patients","volume":"25","author":"Gallotta","year":"2018","journal-title":"J. Minim. Invasive Gynecol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/ALN.0000000000002662","article-title":"Airway Closure during Surgical Pneumoperitoneum in Obese Patients","volume":"131","author":"Grieco","year":"2019","journal-title":"Anesthesiology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/ijgc-2022-003904","article-title":"Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer","volume":"33","author":"Conte","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1001\/jamaoncol.2021.4252","article-title":"Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer","volume":"7","author":"Melamed","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1245\/s10434-013-3091-6","article-title":"Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy","volume":"20","author":"Petrillo","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ygyno.2022.03.024","article-title":"The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery","volume":"165","author":"Bizzarri","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejrad.2008.02.019","article-title":"CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: A systematic review and meta-analysis","volume":"71","author":"Gu","year":"2009","journal-title":"Eur. J. Radiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.3802\/jgo.2023.34.e31","article-title":"The value of PET\/CT for cytoreductive surgery selection in recurrent ovarian carcinoma","volume":"34","author":"Nunes","year":"2023","journal-title":"J. Gynecol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jmig.2017.12.023","article-title":"Role of Intraoperative Ultrasound to Extend the Application of Minimally Invasive Surgery for Treatment of Recurrent Gynecologic Cancer","volume":"25","author":"Mascilini","year":"2018","journal-title":"J. Minim. Invasive Gynecol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1245\/s10434-014-4011-0","article-title":"Positron emission tomography-laparoscopy based method in the prediction of complete cytoreduction in platinum-sensitive recurrent ovarian cancer","volume":"22","author":"Fanfani","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000159266","article-title":"A treatment selection protocol for recurrent ovarian cancer patients: The role of FDG-PET\/CT and staging laparoscopy","volume":"75","author":"Fagotti","year":"2008","journal-title":"Oncology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.ajog.2004.11.018","article-title":"The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers","volume":"192","author":"Chi","year":"2005","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"50.e1","DOI":"10.1016\/j.ajog.2016.08.030","article-title":"Laparoscopic staging for apparent stage I epithelial ovarian cancer","volume":"216","author":"Melamed","year":"2017","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.suronc.2010.08.006","article-title":"Re-operation outcome in patients referred to a gynecologic oncology center with presumed ovarian cancer FIGO I-IIIA after sub-standard initial surgery","volume":"21","author":"Grabowski","year":"2012","journal-title":"Surg. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"58.e1","DOI":"10.1016\/j.ajog.2013.04.013","article-title":"Staging laparoscopy for the management of early-stage ovarian cancer: A metaanalysis","volume":"209","author":"Park","year":"2013","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"83.e1","DOI":"10.1016\/j.ajog.2008.08.013","article-title":"Laparoscopic management of early ovarian and fallopian tube cancers: Surgical and survival outcome","volume":"200","author":"Nezhat","year":"2009","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaoncol.2020.1702","article-title":"Minimally Invasive Surgery and Risk of Capsule Rupture for Women With Early-Stage Ovarian Cancer","volume":"6","author":"Matsuo","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jmig.2014.11.008","article-title":"Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: A retrospective cohort study on perioperative outcomes","volume":"22","author":"Fagotti","year":"2015","journal-title":"J. Minim. Invasive Gynecol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jmig.2017.10.024","article-title":"Secondary Laparoscopic Cytoreduction in Recurrent Ovarian Cancer: A Large, Single-Institution Experience","volume":"25","author":"Gallotta","year":"2018","journal-title":"J. Minim. Invasive Gynecol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.3802\/jgo.2016.27.e24","article-title":"Feasibility of laparoscopic cytoreduction in patients with localized recurrent epithelial ovarian cancer","volume":"27","author":"Paik","year":"2016","journal-title":"J. Gynecol. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"102391","DOI":"10.1016\/j.bpobgyn.2023.102391","article-title":"Robotic surgery in ovarian cancer","volume":"90","author":"Gallotta","year":"2023","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/ijgc-2022-004255","article-title":"Laparoscopic secondary cytoreductive surgery: Let\u2019s not make the same assumptions","volume":"33","author":"Ramirez","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ygyno.2016.04.537","article-title":"Surgical management of recurrent ovarian cancer","volume":"142","author":"Suh","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ygyno.2006.10.020","article-title":"Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer","volume":"104","author":"Santillan","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ygyno.2006.06.039","article-title":"Isolated lymph node relapse of epithelial ovarian carcinoma: Outcomes and prognostic factors","volume":"104","author":"Blanchard","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ygyno.2009.04.025","article-title":"Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer","volume":"114","author":"Fotiou","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ejso.2013.11.026","article-title":"Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: A multicenter study","volume":"40","author":"Ferrero","year":"2014","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Legge, F., Petrillo, M., Adamo, V., Pisconti, S., Scambia, G., and Ferrandina, G. (2008). Epithelial ovarian cancer relapsing as isolated lymph node disease: Natural history and clinical outcome. BMC Cancer, 8.","DOI":"10.1186\/1471-2407-8-367"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijsu.2019.07.026","article-title":"Survival outcomes of ovarian cancer patients treated with secondary cytoreductive surgery for isolated lymph node recurrence: A systematic review of the literature","volume":"69","author":"Pergialiotis","year":"2019","journal-title":"Int. J. Surg."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/j.1525-1438.2007.00929.x","article-title":"Bulky lymph node resection in patients with recurrent epithelial ovarian cancer: Impact of surgery","volume":"17","author":"Panici","year":"2007","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ygyno.2009.11.008","article-title":"The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: A multicenter retrospective Italian study","volume":"116","author":"Gadducci","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1245\/ASO.2004.11.023","article-title":"Outcomes after combined therapy including surgical resection in patients with epithelial ovarian cancer recurrence(s) exclusively in lymph nodes","volume":"11","author":"Uzan","year":"2004","journal-title":"Ann. Surg. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.ejso.2020.01.035","article-title":"Salvage lymphadenectomy in recurrent ovarian cancer patients: Analysis of clinical outcome and BRCA1\/2 gene mutational status","volume":"46","author":"Gallotta","year":"2020","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.ejso.2018.08.006","article-title":"Minimally invasive salvage lymphadenectomy in gynecological cancer patients: A single institution series","volume":"44","author":"Gallotta","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1245\/s10434-021-11267-5","article-title":"Minimally Invasive Secondary Cytoreductive Surgery for Superficial Celiac and Cardio-Phrenic Isolated Nodal Recurrence of Ovarian Cancer","volume":"29","author":"Loverro","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1245\/s10434-017-6005-1","article-title":"Hepatoceliac Lymph Node Involvement in Advanced Ovarian Cancer Patients: Prognostic Role and Clinical Considerations","volume":"24","author":"Gallotta","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.ejso.2019.06.023","article-title":"Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases","volume":"45","author":"Gallotta","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ygyno.2005.10.037","article-title":"Laparoscopic and hand-assisted laparoscopic splenectomy for recurrent and persistent ovarian cancer","volume":"101","author":"Chi","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Macci\u00f2, A., Sanna, E., Lavra, F., Chiappe, G., Petrillo, M., and Madeddu, C. (2021). Laparoscopic splenectomy both for primary cytoreductive surgery for advanced ovarian cancer and for secondary surgery for isolated spleen recurrence: Feasibility and technique. BMC Surg., 21.","DOI":"10.1186\/s12893-021-01368-z"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/icvts\/ivab216","article-title":"Prognostic factors for survival in patients with lung metastases from gynaecological tract cancers","volume":"34","author":"Chiappetta","year":"2022","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jmig.2018.02.014","article-title":"Concomitant Laparoscopic and Thoracoscopic Resection of Recurrent High-Grade Ovarian Cancer","volume":"25","author":"Tozzi","year":"2018","journal-title":"J. Minim. Invasive Gynecol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000209320","article-title":"Video-assisted thoracoscopic surgery for recurrent ovarian cancer with a metastatic mediastinal mass","volume":"32","author":"Ki","year":"2009","journal-title":"Onkologie"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Avesani, G., Tran, H.E., Cammarata, G., Botta, F., Raimondi, S., Russo, L., Persiani, S., Bonatti, M., Tagliaferri, T., and Dolciami, M. (2022). CT-Based Radiomics and Deep Learning for BRCA Mutation and Progression-Free Survival Prediction in Ovarian Cancer Using a Multicentric Dataset. Cancers, 14.","DOI":"10.3390\/cancers14112739"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.rcl.2023.02.006","article-title":"Radiomics and Radiogenomics of Ovarian Cancer: Implications for Treatment Monitoring and Clinical Management","volume":"61","author":"Panico","year":"2023","journal-title":"Radiol. Clin. N. Am."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/19\/4769\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:00:36Z","timestamp":1760130036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/19\/4769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":81,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["cancers15194769"],"URL":"https:\/\/doi.org\/10.3390\/cancers15194769","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,28]]}}}